We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBGM Group Ltd.

BGM Group Ltd.

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
8.01 USD 0.00(0%)
Last update at 2026-11-11T14:30:00Z
Market Cap
73.07M

Momentum Score

…

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform. BGM Group Ltd. is based in Chengdu, China.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.01
Low
8.01
High
52 Week Price Range
0.27
Low
17.17
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Qilian International Holding Group Limited (NASDAQ: BGM) are sparse and do not clearly describe the company's core operations or revenue mix. Because long-term growth drivers are not well documented, potential upside appears to hinge on management execution, segment expansion and improved public reporting. Investors may find exposure to a small-cap international holding structure attractive if operational clarity and governance strengthen.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.01
Dividend Yield
-
Revenue TTM
29.87M
Revenue Per Share
4.18
Gross Profit TTM
0.87M
Debt / Equity
-
ROE
-16.52%
Net Debt
-9.82M
ROCE
-0.81%
Diluted EPS TTM
-0.29

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-09-30 2023-09-30 2022-09-30 2021-09-30 2020-09-30
Type yearly yearly yearly yearly yearly
Date 2024-09-30 2023-09-30 2022-09-30 2021-09-30 2020-09-30
Income before tax -2.14M -7.90M 1.56M 3.36M 5.81M
Minority interest 0.07M 0.34M -0.29M 0.04M 0.12M
Net income -1.44M -7.78M 1.08M 3.15M 5.06M
Selling general administrative 2.72M 4.36M 4.13M 3.25M 2.73M
Selling and marketing expenses 0.59M - - - -
Gross profit 4.11M 1.75M 6.23M 5.64M 7.54M
Reconciled depreciation 1.24M 1.14M 1.22M 1.20M 1.17M
Ebit -0.36M - - - -
Ebitda 0.88M - - - -
Depreciation and amortization 1.24M - - - -
Operating income -0.56M -2.42M 2.52M 2.95M 5.89M
Other operating expenses 25.66M - - - -
Interest expense 0.64M - - 0.06M 0.24M
Tax provision -0.62M 0.22M 0.19M 0.26M 0.86M
Interest income - - 0.02M - -
Net interest income -0.64M 0.10M 0.02M -0.06M -0.24M
Income tax expense -0.62M - - - -
Total revenue 25.10M 46.47M 64.86M 57.10M 50.03M
Total operating expenses 4.68M 48.89M 62.34M 54.15M 44.14M
Cost of revenue 20.98M 44.72M 58.63M 51.46M 42.49M
Total other income expense net -1.57M -5.58M -0.98M 0.47M 0.16M
Net income from continuing ops -1.52M -8.12M 1.37M 3.11M 4.94M
Breakdown 2024-09-30 2023-09-30 2022-09-30 2021-09-30 2020-09-30
Type yearly yearly yearly yearly yearly
Date 2024-09-30 2023-09-30 2022-09-30 2021-09-30 2020-09-30
Total assets 53.00M 51.26M 64.53M 75.35M 48.14M
Intangible assets 4.54M 3.42M 1.73M 1.93M 1.88M
Other current assets 0.80M - -0.00M - -
Total liab 8.91M 6.91M 9.56M 18.68M 19.30M
Total stockholder equity 42.74M 42.79M 53.05M 54.86M 26.10M
Other current liab 3.77M - - - -
Common stock 0.06M - - - -
Capital stock 0.06M 0.06M 0.06M 0.06M 0.05M
Retained earnings 4.35M 5.90M 15.51M 14.69M 12.20M
Cash 9.82M 7.48M 14.32M 10.47M 11.87M
Total current liabilities 8.78M 6.66M 9.18M 18.17M 18.42M
Current deferred revenue 0.57M - - - -
Net debt -9.82M - - - -
Short long term debt - 0.48M 1.67M 7.87M 7.35M
Other stockholder equity 36.41M - - - -
Total current assets 29.77M 34.51M 30.03M 40.37M 37.52M
Long term investments 3.36M 0.61M 20.09M 20.96M 0.54M
Short term investments 8.32M 14.94M 0.00M - -
Net receivables 5.77M 1.98M 0.82M 1.73M 1.12M
Inventory 5.05M 4.99M 8.88M 12.50M 11.99M
Accounts payable 4.13M 3.59M 5.29M 6.64M 4.38M
Accumulated other comprehensive income 1.92M - - - -
Non currrent assets other - - 0.17M 0.19M 0.18M
Non current assets total 23.23M 16.75M 34.49M 34.99M 10.63M
Capital lease obligations 0.00M 0.10M 0.10M 0.16M 0.24M
Breakdown 2024-09-30 2023-09-30 2022-09-30 2021-09-30 2020-09-30
Type yearly yearly yearly yearly yearly
Date 2024-09-30 2023-09-30 2022-09-30 2021-09-30 2020-09-30
Investments 0.98M -4.74M -3.26M -24.20M -0.38M
Total cashflows from investing activities 0.98M - - - -
Net borrowings -0.49M - - - -
Total cash from financing activities -0.49M -2.92M -5.94M 23.99M 2.14M
Net income -1.52M -7.78M 1.08M 3.15M 5.06M
Change in cash 2.34M -7.50M 2.37M 0.74M 7.27M
Begin period cash flow 7.48M 14.98M 12.61M 11.87M 4.59M
End period cash flow 9.82M 7.48M 14.98M 12.61M 11.87M
Total cash from operating activities 0.54M 0.31M 12.65M 0.35M 5.08M
Issuance of capital stock - 0.00M 0.00M 23.87M 0.00M
Depreciation 1.24M 1.14M 1.22M 1.20M 1.17M
Other cashflows from investing activities -1.02M - - - -
Dividends paid 0.00M 1.79M 0.00M - 0.00M
Change to inventory 0.96M 3.40M 2.23M 0.05M 1.40M
Change to account receivables 1.33M -1.22M 1.03M -0.55M -0.66M
Capital expenditures 3.93M 3.71M 3.26M 3.49M 0.46M
Change in working capital 0.79M 1.11M 8.75M -3.67M -0.79M
Stock based compensation 0.00M 0.00M 0.02M 0.00M 0.00M
Other non cash items 0.45M 0.03M 0.02M 0.06M -
Free cash flow -3.39M -3.40M 9.40M -3.15M 4.62M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BGM
BGM Group Ltd.		 -
-%		 8.01 - - 0.26 0.40 2.25 -2.48
MKKGY
Merck KGaA ADR		 -0.74
2.19%		 33.06 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -
-%		 170.05 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.34
1.66%		 21.18 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.72 - 10.66 0.01 1.16 2.94 23.11

Profile*

BGM Group Ltd.

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform. BGM Group Ltd. is based in Chengdu, China.

No. 152 Hongliang East 1st Street, Chengdu, China, 610200

86 28 6477 5180

https://www.bgmgroupltd.com

298

Name Title Year Born
Mr. Zhanchang Xin Chairman of the Board, President, COO & Chief Scientific Officer 1967
Mr. Chen Xin Chief Executive Officer 1993
Ms. Yaxuan Zhai Chief Financial Officer 1995
Mr. Chen Xin CEO, VP of Duxiaobao Management Committee & Chairman 1994
Mr. Yuqing Li Co-Chief Executive Officer NA
Ms. Yaxuan Zhai Chief Financial Officer 1996

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…